The European medical device safety framework is entering a new and very concrete phase. With the mandatory implementation, since May 28, 2026, of the first four EUDAMED modules, the European Union is strengthening the traceability, transparency, and monitoring of everything placed on the market, including through digital channels. For online retailers, this is not simply an administrative adjustment: it represents a profound change in how they list, present, distribute, and track products.
This development particularly affects connected devices, healthcare software, and, more broadly, all products at the intersection of e-commerce and medical monitoring. In an environment where European consumers are seeking greater clarity, compliance, and proof of quality, the new European safety standard is pushing the market toward greater rigor. Here's what you need to know to understand the implications for online sales and post-market surveillance.
EUDAMED becomes a key player in European traceability
Since May 28, 2026, the European Commission has made the first four modules of EUDAMED mandatory: Actor registration, UDI/Device registration, Notified Bodies & Certificates , and Market Surveillance. In practical terms, this strengthens the ability of authorities and operators to identify who is selling what, under what regulatory basis, and with what level of compliance. For online sales, this means it becomes much more difficult to remain vague about the seller's identity or the exact status of the device.
EUDAMED was conceived as a “live” view of the medical device lifecycle in the European Union. This approach is a game-changer for distance selling, as the focus is no longer solely on market access, but also on continuous monitoring. A product sheet, a UDI identifier, a certificate, and a tracking history now form a more coherent package in the eyes of authorities, healthcare professionals, and the public.
For buyers, this development is a step in the right direction. In any security-sensitive market, transparency provides reassurance. When a product is better identified, better registered, and more easily traceable, it reduces the risk of errors, confusion, or the circulation of poorly documented products. It also sends a strong signal to reputable sellers who are already investing in quality, compliance, and traceability.
Online marketing under a higher level of requirements
The new European safety standard has a direct consequence: online sales are becoming more regulated. Sellers and platforms must better document the products they offer, verify their regulatory status, and ensure that the information visible to users is consistent with MDR or IVDR requirements. The days of vague product descriptions or overly marketing-oriented titles without a clear basis are dwindling.
This increased stringency is part of a broader context. The MDR has been in effect since May 26, 2021, and the IVDR since May 26, 2022, with a stronger emphasis on safety, performance, and vigilance. The adjustments introduced by Regulations 2023/607 and 2024/1860 have also demonstrated that the European Union is seeking to avoid market disruptions while continuing to strengthen the compliance framework. In short, the goal is not to block the market, but to make it more reliable.
For online retailers, this means more structured work on product listing, proof of compliance, and document governance. In sectors where trust is essential, this dynamic can also become a competitive advantage. Companies that clearly communicate about the legality, testing, origin, and quality of their products are already aligning with the growing expectations of European consumers regarding safety.
Online medical applications are now in the crosshairs
In June 2025, the Commission published guidance MDCG 2025-4, entitled Guidance on the safe making available of medical device software (MDSW) apps on online platforms. While this guidance is not legally binding, it has significant practical implications, as it harmonizes the interpretation of the rules applicable to medical device software on online platforms and app stores.
This publication sends a very clear message: health apps can no longer be treated as mere generic digital products. Their identification, distribution methods, the quality of user information, and their market positioning must be consistent with their regulatory classification. When the Commission points out that approximately one in four devices incorporates software, it becomes clear why the pressure is mounting on this segment.
The implications for online sales are significant. A medical device application sold or downloaded from a platform must be considered a healthcare product in its own right. Digital solution providers must therefore work proactively with platforms, distributors, and compliance officers to avoid inconsistencies between the marketing promise, the product's intended medical use, and safety requirements.
When digitalization accelerates, obligations do not disappear
The European Commission is clearly pushing towards digitalization. On June 25, 2025, it announced that healthcare professionals can now receive instructions for use electronically, and not just on paper. This development aims to modernize care, reduce administrative burdens, and support sustainability, while maintaining the option to request a paper copy.
This advancement is significant for the sale and distribution of devices, especially through digital channels. User information, updates, precautions, and warnings can circulate more quickly. For connected products or software, this allows for more responsive support and better content updates. However, this digital flexibility does not lower the standards; it shifts them toward the quality of distribution, the accessibility of information, and the accuracy of the provided documentation.
In other words, digitization doesn't mean oversimplification. Operators must demonstrate that users receive clear, relevant, and personalized information. In the e-commerce world, this is crucial: the smoother the distribution process, the more fundamental the responsibility for providing accurate information becomes. Modernizing platforms never replaces regulatory rigor.
Post-marketing medical monitoring is becoming a strategic issue
Post-market medical follow-up is no longer a purely technical matter reserved for regulatory teams. The MDR mandates ongoing clinical evaluation, a clinical development plan, and structured collection of clinical data, including post-market data. This means that a product's life cycle doesn't begin or end with its online launch or first sale.
The Commission reiterates that post-market clinical follow-up (PMCF) is an ongoing process. This distinction is fundamental. It requires manufacturers to actively monitor the performance and risks of their devices under real-world conditions. For connected devices, medical software, and remote solutions, this requirement is even more critical, as feedback from the field can be plentiful, rapid, and technically complex.
In practice, online sales and medical monitoring are becoming increasingly intertwined. User reviews are obviously insufficient to constitute clinical evidence, but usage data, reported incidents, support requests, and observed trends can inform post-market surveillance. Product management must therefore link sales, service, compliance, and security within a single operational framework.
Vigilance and PMS become the two pillars of post-marketing
The Commission's documents now clearly structure the topic around a "Post-Market Surveillance and Vigilance (PMSV)" framework. This regulatory structure demonstrates that post-market surveillance and vigilance form the two pillars of post-market monitoring. The objective is not simply to identify problems, but to detect early warning signs more quickly, take action, and reduce the likelihood of recurrence.
The MDCG 2025-10 guidance, published in December 2025 on post-market surveillance of medical devices and IVDs, confirms this tightening of practical requirements. Even when guidance does not have the direct force of a regulation, it strongly influences how authorities, notified bodies, and economic operators interpret expected best practices. The market then understands that a higher level of maturity is required.
For online retailers, this shift has tangible consequences. It requires incident reporting procedures, improved coordination with manufacturers, more robust complaints management, and the ability to quickly withdraw or correct a product if necessary. Safety is no longer solely a matter of the initial listing; it must be managed over time, throughout the product's actual use.
Platforms and marketplaces also play an increasing role
The link between online commerce and product safety is strengthened by market surveillance. The Council of the European Union reiterates that online marketplaces have obligations under general product safety regulations and the Digital Services Act. This means that platforms can no longer consider themselves mere neutral storefronts when it comes to sensitive products.
National market surveillance authorities can impose corrective actions and monitor the situation when a security issue is detected. In practice, this encourages platforms to collaborate more effectively with sellers, streamline the removal of problematic listings, and require more robust data on operator identity and product compliance. The era of minimal oversight is gradually fading.
For reputable brands, this context can be positive. The more evidence marketplaces demand, the more well-structured players gain visibility and credibility. In a European market increasingly focused on quality, the ability to demonstrate compliance, traceability, and safety becomes a genuine business driver, not just a regulatory requirement.
Product availability and safety: a new duo to watch
European regulations are no longer solely concerned with the pure conformity of devices, but also with their availability on the market. The changes introduced by Regulation 2024/1860, particularly regarding the notification of supply interruptions and the gradual deployment of EUDAMED, demonstrate that continuity of access is becoming a major operational issue.
The Commission also mentioned in July 2026 the publication of a dashboard to monitor the availability of devices on the EU market. This is an important signal: European surveillance is not only focused on medical or technical risks, but also on supply shortages that could affect professionals and patients. Market monitoring is therefore becoming more comprehensive.
For online sales, this means more precise management of inventory, product references, substitutions, and customer information. When a product is out of stock, changes versions, or is subject to corrective action, transparency becomes essential. Modern European security is no longer limited to initial authorization; it includes availability, continuity, and responsiveness throughout the entire supply chain.
Ultimately, the new European safety standard significantly strengthens the link between online marketing and medical monitoring. With EUDAMED mandatory for its initial modules, the MDCG 2025-4 guidance on apps, the enhanced framework for post-market surveillance, and the focus on platforms, the market is moving towards a more continuous, more digital, and more field-connected approach to control.
For companies selling sensitive products online, the right approach is not to wait for yet another constraint, but to build a culture of traceability, clear information, and rigorous monitoring. In the Europe of 2026, selling online is no longer just about being visible and fast: it's also about being able to prove, document, and correct. This combination of innovation, transparency, and security will define the strongest players of tomorrow.
